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An overview of surveillance methods and systems for Salmonella infections is available at  
http://www.cdc.gov/nationalsurveillance/PDFs/NationalSalmSurveillOverview_508.pdf (1).
Human Surveillance Data: Laboratory-based Enteric Disease Surveillance (LEDS)
The Laboratory-based Enteric Disease Surveillance (LEDS) system collects reports of laboratory-confirmed human 
Salmonella isolates from state public health laboratories.  Reporting to LEDS is voluntary, and the number of states 
submitting reports varies somewhat from year to year although almost all states report every year.  Serotypes 
are summarized in this annual report as reported by state laboratories; they are usually not confirmed by CDC.  
Occasionally, more than one isolate is reported from a single episode of infection in a person; this report includes 
only one isolate of a given Salmonella serotype per person within a 30-day period. 
In this report, we summarize the number of infections reported and also report incidence rates (cases per 100,000 
population), which are calculated as the number of Salmonella infections in humans reported for a given year 
divided by the state population for that year. 
Data were received from all 51 reporting jurisdictions (50 states plus the District of Columbia) in 2011.  For maps 
(Figures 2a to 2h), data was excluded from states where
 • the number of laboratory-confirmed human Salmonella isolates reported to LEDS was less than 20% of the 
number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS):
 » 7 reporting jurisdictions were excluded: Florida, Kansas, Louisiana, Mississippi, New Hampshire, Nevada, 
Tennessee
 • the number of fully serotyped laboratory-confirmed human Salmonella isolates reported to LEDS was less than 
20% of Salmonella isolates reported to LEDS:
 » 7 reporting jurisdictions were excluded: Kentucky, Maine, Montana, Nebraska, Texas, Vermont, Wyoming
Data in this report current as of 1/14/2013.
Colorized scanning electron micrograph (SEM) of clustered Gram-negative 
Salmonella typhimurium bacteria.
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Table 1. Laboratory-confirmed human Salmonella infections reported to CDC, with the 20 most frequently 
reported serotypes listed individually, United States, 2011
Rank Serotype Number Reported Percent
1 Enteritidis 7553 16.5
2 Typhimurium (including Typhimurium var. 5-) 6131 13.4
3 Newport 5211 11.4
4 Javiana 2937 6.4
5 I 4,[5],12:i:- 1339 2.9
6 Montevideo 1196 2.6
7 Heidelberg 1103 2.4
8 Muenchen 984 2.1
9 Infantis 910 2.0
10 Branderup 739 1.6
11 Oranienburg 721 1.6
12 Saintpaul 709 1.5
13 Mississippi 549 1.5
14 Thompson 536 1.2
15 Agona 505 1.1
16 Paratyphi B var. L(+) tartrate+ 431 0.9
17 Bareilly 429 0.9
18 Typhi 383 0.8
19 Berta 321 0.7
20 Anatum 282 0.6
Sub Total 32969 71.9
All Other Serotyped 6864 15.0
Unknown 4173 9.1
Partially serotyped 1603 3.5
Rough, mucoid, and/or nonmotile isolates 219 0.5
Sub Total 12859 28.1
Total 45828 100
All serotyped isolates are listed in Table 3
State public health laboratories reported 45,828 laboratory-confirmed Salmonella infections to CDC 
through LEDS
 • The top 4 serotypes in 2011 were Enteritidis (17%), Typhimurium (including Typhimurium var. 5- ) 
(13%), Newport (11%) and Javiana (6%).
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Table 2. Laboratory-confirmed human Salmonella infections reported to CDC, percent change among the 20 most 
frequently reported serotypes, comparing 2001, 1006, and 2011 
Rank Number Reported Percent Change










2 2 1 Enteritidis 5613 6740 7553 20 12 35
1 1 2 Typhimurium* 7040 6866 6131 -2 -11 -13
3 3 3 Newport 3168 3373 5211 6 54 64
5 5 4 Javiana 1068 1433 2937 34 105 175
20 6 5 I 4,[5],12:i:- 297 1233 1339 315 9 351
6 7 6 Montevideo 628 1061 1196 69 13 90
4 4 7 Heidelberg 1895 1495 1103 -21 -26 -42
8 8 8 Muenchen 586 753 984 28 31 68
12 14 9 Infantis 441 491 910 11 85 106
13 12 10 Braenderup 396 561 739 42 32 87
7 9 11 Oranienburg 598 719 721 20 0 21
10 11 12 Saintpaul 471 588 709 25 21 51
16 10 13 Mississippi 336 604 549 80 -9 63
9 15 14 Thompson 514 447 536 -13 20 4
14 13 15 Agona 372 538 505 45 -6 36
11 16 16 Paratyphi B var. L(+) tartrate+ 466 417 431 -11 3 -8
21 21 17 Bareilly 206 256 429 24 68 108
15 17 18 Typhi 343 413 383 20 -7 12
17 22 19 Berta 334 252 321 -25 27 -4
22 24 20 Anatum 188 238 282 27 18 50
Note:  * Typhimurium includes var. 5- (formerly var. Copenhagen)
Although reports of serotype I 4,[5],12:i:- increased 351% in 2011 from 2001, this reflects, for the most part, a 
change in reporting practice (1).
 • In 2011, serotype Javiana had the largest increase (250%) since 2001 of any of the top 20 serotypes for which 
surveillance has been stable; most of this increase occurred after 2006.
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Figure 1. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC (all serotypes and 

































































































































Serotype Montevideo Serotype Unknown/Partial/Rough
Serotype Newport
Serotype Heidelberg
Serotype Javiana Serotype I,4,[5],12:i:-
All Salmonella Serotype Typhimurium (including var. 5-)Serotype Enteritidis
The top panel of this graph shows the incidence rate of infection with Salmonella (all serotypes) and with 
serotypes Typhimurium (including serotype Typhimurium var. 5-) and Enteritidis from 1970 to 2011
 • Since 1970, the incidence rate of infection with all Salmonella has been driven largely by the incidence rate of 
infection with serotypes Typhimurium (including serotype Typhimurium var. 5-) and Enteritidis
 • The spike in incidence rate seen in 1985 reflects an outbreak of Salmonella serotype Typhimurium infections 
associated with pasteurized milk (2)
The bottom panel of this graph shows the incidence rate of infection with all serotypes of Salmonella with more 
than 1000 infections reported to CDC in 2011: this includes serotypes Newport, Javiana, I, 4,[5],12:i:-, Heidelberg, 
Montevideo, and infections with an unknown, rough, or partial serotype 
 • The incidence rate of infection with serotype Heidelberg has been decreasing steadily following a peak in 1987
 • Since the late 1990s, the incidence rates of infection with serotypes Javiana, Newport, and I,4,[5],12:i:- have 
been steadily increasing 
 • Since 2000, the incidence of infection with isolates with an unknown, rough, or partial serotype have been 
increasing
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Figure 2a. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC (all serotypes), 
by state, United States, 2011*
8.16–9.91
Legend





* Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Kansas, 
Louisiana, Mississippi, New Hampshire, Nevada, Tennessee) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Vermont, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of Salmonella infection (cases per 100,000 
population) were Alabama (35.2), South Carolina (32.1), and North Carolina (27.6).
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Figure 2b. Incidence rate of laboratory-confirmed human Salmonella serotype Enteritidis infection reported to CDC, 
by state, United States, 2011*
1.49–1.96
Legend





*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming). 
The reporting jurisdictions with the highest reported incidence rates of serotype Enteritidis infection (cases per 
100,000 population) were the District of Columbia (6.5), Wisconsin (6.0), and Connecticut (5.8). 
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Figure 2c. Incidence rate of laboratory-confirmed human Salmonella serotype Typhimurium (including 
Typhimurium var. 5-) infection reported to CDC, by state, United States, 2011*
0.97–1.34
Legend





*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Typhimurium (including 
Typhimurium var. 5-) infection (cases per 100,000 population) were South Dakota (8.6), Alabama (6.3), and 
Hawaii (5.7). 
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Figure 2d. Incidence rate of laboratory-confirmed human Salmonella serotype Newport infection reported to CDC, 
by state, United States, 2011*
0.34–0.65
Legend





*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Newport infection (cases per 
100,000 population) were South Carolina (6.8), Arkansas (6.8), North Carolina (6.3). 
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Figure 2e. Incidence rate of laboratory-confirmed human Salmonella serotype Javiana infection reported to CDC, 







Rate per 100,000 population
Legend
*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming). Reporting 
jurisdictions shaded with grey lines are those that were not excluded from mapping but that reported no infections with this serotype. 
The reporting jurisdictions with the highest reported incidence rates of serotype Javiana infection (cases per 
100,000 population) were South Carolina (8.0), North Carolina (5.5), and Georgia (5.1). 
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Figure 2f. Incidence rate of laboratory-confirmed human Salmonella serotype I,4,[5],12:i:- infection reported to CDC, 
by state, United States, 2011* 
0.02–0.31
No infections reported






*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  Reporting 
jurisdictions shaded with grey lines are those that were not excluded from mapping but that reported no infections with this serotype. 
The reporting jurisdictions with the highest reported incidence rates of serotype I,4,[5],12:i:- infection (cases per 
100,000 population) were Minnesota (1.3), Iowa (1.2), and Alabama (1.1).  
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Figure 2g. Incidence rate of laboratory-confirmed human Salmonella serotype Heidelberg infection reported to 
CDC, by state, United States, 2011* 
0.05–0.22
Legend





*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Heidelberg infection (cases per 
100,000 population) were Rhode Island (5.1), Hawaii (1.3), and New Jersey (1.1).
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Figure 2h. Incidence rate of laboratory-confirmed human Salmonella serotype Montevideo infection reported to 
CDC, by state, United States, 2011* 
0.03–0.16
No infections reported






*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  Reporting 
jurisdictions shaded with grey lines are those that were not excluded from mapping but that reported no infections with this serotype. 
The reporting jurisdictions with the highest reported incidence rates of serotype Montevideo infection (cases per 
100,000 population) were Alabama (1.9), Pennsylvania (1.2), and South Carolina (1.0). 
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Figure 3. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC, by age group 
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During 2011, the highest incidence rate of Salmonella infections was in children under 5 years old.  From ages 0 
to 19, males had a higher incidence rate of Salmonella  infections than females; from age 20 to 80+, females had a 
higher incidence rate of Salmonella infections than males.
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Figure 4. Number of laboratory-confirmed human Salmonella infections reported to CDC, by month of specimen 
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Compared with the previous 10 years (2001-2010), more Salmonella infections were reported in 2011.  During  
2011, reports of Salmonella infections showed seasonality similar to the average reported during 2001 to 2010, 
with a summer peak and the largest number of infections reported in August.
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Human Surveillance Data: National Notifiable Diseases  
Surveillance System (NNDSS)
The National Notifiable Disease Surveillance System (NNDSS) collects and compiles reports of nationally notifiable 
infectious diseases, including salmonellosis.  This system includes reports of laboratory-confirmed cases and 
probable cases (clinically compatible cases with an epidemiological link to a confirmed case). 
The report for 2011 was not available when this was written.  Reports are available at  
http://www.cdc.gov/mmwr/mmwr_nd/index.html 
Human Antimicrobial Resistance Data: National Antimicrobial Resistance 
Monitoring System (NARMS)
The National Antimicrobial Resistance Monitoring System (NARMS) monitors antimicrobial resistance among 
enteric bacteria (including Salmonella) isolated from humans.  As of March 2013, the 2011 NARMS annual report 
was not yet available.  The report for 2011 was not available when this was written.  Reports are available at  
http://www.cdc.gov/narms/reports.html 
Human Outbreak Data: Foodborne Disease Outbreak Surveillance System 
(FDOSS) and Waterborne Disease Outbreak Surveillance System (WBDOSS)
The Foodborne Disease Outbreak Surveillance System (FDOSS) collects reports of foodborne disease outbreaks 
from local, state, tribal, and territorial public health agencies.  The report for 2011 was not available when this was 
written.  Reports are available at  
http://www.cdc.gov/outbreaknet/surveillance_data.html.
The Waterborne Disease and Outbreak Surveillance System (WBDOSS) collects reports of waterborne disease 
outbreaks associated with drinking water and recreational water from local, state, tribal, and territorial public 
health agencies.  The report for 2011 was not available when this was written.  Reports are available at  
http://www.cdc.gov/healthywater/statistics/wbdoss/surveillance.html.
Non-human Surveillance Data: National Veterinary Services Labortories (NVSL)
The data in tables 3, 4, and 5 come from the National Veterinary Services Laboratories (NVSL) of the United States 
Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS).  Isolates from Salmonella 
infections are submitted to NVSL by veterinary diagnostic laboratories throughout the United States for serotyping. 
Clinical animal infections (referred to as “clinical/non-human”) are Salmonella infections from animals with clinical 
signs of illness; “non-clinical/non-human” infections are Salmonella infections identified through herd and flock 
monitoring and surveillance, feed sample testing, environmental testing, and USDA-FSIS food testing programs.   
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Table 3a. Laboratory-confirmed Salmonella isolates from clinical non-human sources submitted to the National 
Veterinary Services Laboratories (NVSL) for typing, with the 20 most frequently reported serotypes 
listed individually, 2011
Clinical Non-human 2011
Rank Serotype Reported Percent
1 Typhimurium* 954 19.7
2 Dublin 323 6.7
3 Cerro 283 5.8
4 Agona 272 5.6
5 Derby 218 4.5
6 Newport 213 4.4
7 Infantis 194 4.0
8 Enteritidis 178 3.7
9 Montevideo 173 3.6
10 I 4,[5],12:i:- 170 3.5
11 Heidelberg 167 3.4
12 Anatum 121 2.5
13 Senftenberg 114 2.4
14 Kentucky 96 2.0
15 Mbandaka 65 1.3
16 Worthington 59 1.2
17 Ohio 53 1.1
18 Johannesburg 49 1.0
19 Muenchen 47 1.0
20 Javiana 45 0.9
Sub Total 3794 78.3
All Other Serotyped 959 19.8
Rough, mucoid, and/or nonmotile isolates 90 1.9
Sub Total 1049 21.7
Total 4843 100
Note:   
  * Typhimurium includes var. 5- (formerly var. Copenhagen) 
** Choleraesuis includes var. Decatur and Kunzendorf
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Table 3b. Laboratory-confirmed Salmonella isolates from non-clinical non-human sources submitted to the 
National Veterinary Services Laboratories (NVSL) for typing, with the 20 most frequently reported 
serotypes listed individually, 2011 
Non-Clinical Non-human 2010
Rank Serotype Reported Percent
1 Kentucky 668 10.2
2 Enteritidis 521 8.0
3 Senftenberg 458 7.0
4 Typhimurium* 353 5.4
5 Derby 350 5.4
6 Mbandaka 299 4.6
7 Heidelberg 291 4.5
8 Anatum 194 3.0
9 Infantis 164 2.5
10 Hadar 160 2.5
11 Agona 157 2.4
12 Schwarzengrund 144 2.2
13 Tennessee 127 1.9
14 Saintpaul 122 1.9
15 I 4,[5],12:i:- 114 1.7
16 Muenster 107 1.6
17 Newport 97 1.5
18 Montevideo 91 1.4
19 Johannesburg 87 1.3
20 Worthington 82 1.3
Sub Total 4586 70.3
All Other Serotyped 1763 27.0
Rough, mucoid, and/or nonmotile isolates 173 2.7
Sub Total 1936 29.7
Total 6522 100
Note:   
* Typhimurium includes var. 5- (formerly var. Copenhagen)
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Table 4. Laboratory-confirmed Salmonella isolates from clinical non-human animal sources (bovine, chicken, 
porcine, and turkey) submitted to the National Veterinary Services Laboratories (NVSL) for typing, for 
the top 4 serotypes causing human illness in 2011, by source. 
Non-Human (clinical) Sources
Serotype Human Rank, 2011 Bovine (%) Chicken (%) Porcine (%) Turkey (%)
Enteritidis 1 5.6 67.4 2.8 0.6
Typhimurium (including 
Typhimurium var. 5-)
2 20.3 1.8 62.7 0.7
Newport 3 40.9 0.5 5.6 0
Javiana 4 0 0 4.4 0
Table 5. Laboratory-confirmed Salmonella isolates  from non-clinical non-human animal sources (bovine, chicken, 
porcine, and turkey) submitted to the National Veterinary Services Laboratories (NVSL) for typing, for the 
top 4 serotypes causing human illness in 2011, by source.
Non-Human (non-clinical) Sources
Serotype Human Rank, 2011 Bovine (%) Chicken (%) Porcine (%) Turkey (%)
Enteritidis 1 0 92.1 0.8 0.2
Typhimurium (including 
Typhimurium var. 5-)
2 0.9 38.2 40.0 11.3
Newport 3 1.0 62.9 4.1 1.0
Javiana 4 0 42.4 0 12.1
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